Bronfman E.L. Rothschild L.P. cut its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 50.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,856 shares of the exchange traded fund’s stock after selling 1,927 shares during the period. Bronfman E.L. Rothschild L.P.’s holdings in SPDR S&P Biotech ETF were worth $161,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Assetmark Inc. grew its holdings in shares of SPDR S&P Biotech ETF by 59.9% in the third quarter. Assetmark Inc. now owns 1,239,051 shares of the exchange traded fund’s stock worth $107,265,000 after purchasing an additional 464,246 shares during the last quarter. Chatham Capital Group Inc. grew its holdings in shares of SPDR S&P Biotech ETF by 15.4% in the third quarter. Chatham Capital Group Inc. now owns 72,370 shares of the exchange traded fund’s stock worth $6,265,000 after purchasing an additional 9,680 shares during the last quarter. Autus Asset Management LLC grew its holdings in shares of SPDR S&P Biotech ETF by 6.4% in the third quarter. Autus Asset Management LLC now owns 42,122 shares of the exchange traded fund’s stock worth $3,646,000 after purchasing an additional 2,531 shares during the last quarter. AE Wealth Management LLC grew its holdings in shares of SPDR S&P Biotech ETF by 24.1% in the third quarter. AE Wealth Management LLC now owns 3,539 shares of the exchange traded fund’s stock worth $306,000 after purchasing an additional 687 shares during the last quarter. Finally, Banque Pictet & Cie SA grew its holdings in shares of SPDR S&P Biotech ETF by 10.6% in the third quarter. Banque Pictet & Cie SA now owns 151,280 shares of the exchange traded fund’s stock worth $13,096,000 after purchasing an additional 14,450 shares during the last quarter.

SPDR S&P Biotech ETF (NYSEARCA XBI) traded up $0.43 during midday trading on Friday, hitting $81.71. 2,376,500 shares of the stock were exchanged, compared to its average volume of 4,221,887. SPDR S&P Biotech ETF has a 12-month low of $58.66 and a 12-month high of $88.98.

TRADEMARK VIOLATION NOTICE: This news story was originally published by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.watchlistnews.com/spdr-sp-biotech-etf-xbi-shares-sold-by-bronfman-e-l-rothschild-l-p/1724366.html.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with Analyst Ratings Network's FREE daily email newsletter.